Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

被引：0

作者：

Kim, Woosook ^{[1
]}

Fu, Na ^{[1
]}

Duddempudi, Phaneendra ^{[2
]}

Dubeykovskaya, Zinaida ^{[3
]}

Almo, Steven ^{[2
]}

Guha, Chandan ^{[2
]}

Lederman, Seth ^{[4
]}

Wang, Timothy ^{[1
]}

机构：

[1] Columbia Univ, Med Ctr, New York, NY USA

[2] Albert Einstein Coll Med, New York, NY USA

[3] NYU, New York, NY USA

[4] Tonix Pharmaceut Inc, New York, NY USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-6640

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6640

引用

页数：2

共 50 条

[21] PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma [J].

Zhu, Chenzhuang ;

Lin, Sihao ;

Liang, Junhao ;

Zhu, Yingjian .

CRYOBIOLOGY, 2019, 87 :86-90

[22] CD47 BLOCKADE SYNERGIZES WITH PD-1 CHECKPOINT INHIBITOR AND ENHANCES ANTI-TUMOR EFFICACY IN HEPATOCELLULAR CARCINOMA [J].

Kang, Wonseok ;

Kim, Ji-Young ;

Yang, Sera ;

Kang, Sohee ;

Paik, Yong-Han .

HEPATOLOGY, 2019, 70 :1199A-1200A

[23] Rovalpituzumab tesirine enhances the anti-tumor efficacy of PD-1 blockade in a murine model of small cell lung cancer with endogenous 0113 expression [J].

Vitorno, Philip M. ;

Chuang, Chen-Hua ;

Moore, Christine ;

Turan, Tolga ;

Ferrando, Ronald ;

Nichols, Aaron ;

Madhavan, Shravanthi ;

Saunders, Laura R. .

CANCER RESEARCH, 2019, 79 (13)

[24] Entinostat enhances antitumor immune responses and cooperates with PD-1 blockade in bladder cancer mouse models. [J].

Truong, Andrew S. ;

Zhou, Mi ;

Utsumi, Takanobu ;

Krishnan, Bhavani ;

Stewart, Kyle G. ;

Saito, Ryoichi ;

Manocha, Ujjawal ;

Bailey, Sean T. ;

Kim, William Y. .

CLINICAL CANCER RESEARCH, 2020, 26 (15) :37-37

[25] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer [J].

Yinli Yang ;

Ling Li ;

Zhansheng Jiang ;

Bin Wang ;

Zhanyu Pan .

Cancer Immunology, Immunotherapy, 2020, 69 :2523-2532

[26] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer [J].

Yang, Yinli ;

Li, Ling ;

Jiang, Zhansheng ;

Wang, Bin ;

Pan, Zhanyu .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) :2523-2532

[27] Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models [J].

Kandaswamy, Veena ;

Forest, Amelie ;

Deroose, Marianne ;

Schaer, David A. ;

Chen, Ting ;

Liu, Shengwu ;

Surguladze, David ;

Yao, Yung-mae ;

Doman, Thompson ;

Hall, Gerald ;

Wong, Kwok-Kin ;

Kalos, Michael ;

Novosiadly, Ruslan D. .

CANCER RESEARCH, 2018, 78 (13)

[28] Anti-PD-1 and VEGFR2 blockade induces vascular normalization and enhances anti-tumor immune responses in HCC [J].

Shigeta, Kohei ;

Matsui, Aya ;

Aoki, Shuichi ;

Kitagawa, Yuko .

CANCER SCIENCE, 2021, 112 :397-397

[29] Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer [J].

Elloul, Sivan ;

Chang, Hua ;

Klebanov, Boris ;

Kashyap, Trinayan ;

Werman, Maxwell ;

Lee, Margaret ;

Landesman, Yosef ;

Shacham, Sharon ;

Kauffman, Michael ;

Friedlander, Sharon Y. .

CANCER RESEARCH, 2016, 76

[30] Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity [J].

Jiawei Yue ;

Hui Guo ;

Peng Xu ;

Jinhong Ma ;

Weifeng Shi ;

Yumin Wu .

Cancer Immunology, Immunotherapy, 73

← 1 2 3 4 5 →